Antibody

383개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved383 programs
AntibodyLimited DatastaleScripps HealthPreclinical

Cyclophosphamide/Rituximab (Cyclophosphamide/Rituximab)

Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Relapsing-Remitting

#MultipleSclerosisRelapsing-Remit#Antibody#Preclinical#monoclonal-antibody#MultipleSclerosis+2
Trials 1Status Discontinued
AntibodyLimited DatastaleFudan UniversityPreclinical

DEBIRI Combined With Chemotherapy and Bevacizumab (DEBIRI Combined With Chemotherapy and Bevacizumab)

Colorectal Neoplasms · Colorectal Neoplasms

#ColorectalNeoplasms#Antibody#Preclinical#monoclonal-antibody#Fudan
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 1

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex Faspro (Daratumumab and hyaluronidase-fihj))

Hematologic Malignancy; Bone Marrow Transplant Rejection · Hematologic Malignancy

#HematologicMalignancy#Antibody#Phase1#monoclonal-antibody#BoneMarrowTransplantRejection+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCedars-Sinai Medical CenterPhase 1

Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab (Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#Antibody#Phase1#monoclonal-antibody#GlioblastomaMultiforme+1
Trials 1Status Active
AntibodyLimited DatastaleRoche Pharma AGPhase 2

Dinutuximab beta (Dinutuximab beta)

Neuroblastoma · Relapsed Neuroblastoma

#RelapsedNeuroblastoma#Antibody#Phase2#monoclonal-antibody#Neuroblastoma+1
Trials 1Status Active
AntibodyLimited DatastaleGlostrup University Hospital, C…Approved

etanercept or adalimumab (Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity, Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab))

SPONDYLOARTHRITIS · SPONDYLOARTHRITIS

#SPONDYLOARTHRITIS#Antibody#Approved#monoclonal-antibody#Glostrup
Trials 1Status Discontinued
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
AntibodyLimited DatastaleAmgenPhase 3

nivolumab (Opdivo, EU-authorized Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#monoclonal-antibody#Amgen
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 3

daratumumab (Darzalex, Early treatment of relapse with carfilzomib, dexamethasone, daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Illinois at Chica…Phase 3

Elra (Elranatamab, Elranatamab (Elra))

Plasmablastic Lymphoma; Hiv · Plasmablastic Lymphoma

#PlasmablasticLymphoma#Antibody#Phase3#monoclonal-antibody#Hiv+1
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity of Maryland, Baltimo…Phase 2

Erenumab-Aooe (Erenumab-Aooe)

Trigeminal Neuropathy · Trigeminal Neuropathy

#TrigeminalNeuropathy#Antibody#Phase2#monoclonal-antibody#University
Trials 1Status Discontinued
AntibodyLimited DatastaleFundación de Investigación Biom…Preclinical

ustekinumab (Stelara, Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab)

Inflammatory Bowel Disease · Inflammatory Bowel Disease

#InflammatoryBowelDisease#Antibody#Preclinical#monoclonal-antibody#Fundacin
Trials 1Status Active
AntibodyLimited DatastaleAmgenPhase 3

nivolumab (Opdivo, FDA-licensed Nivolumab)

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#monoclonal-antibody#Amgen
Trials 1Status Active
AntibodyLimited DatastaleMedical University of ViennaPhase 2

atezolizumab (Tecentriq, FMT combined with Atezolizumab plus Bevacizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Medical
Trials 1Status Active
AntibodyLimited DatastaleBaylor College of MedicinePhase 1

GINAKIT cells + Etanercept (GINAKIT cells + Etanercept)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#Antibody#Phase1#monoclonal-antibody#Baylor
Trials 1Status Recruiting
AntibodyLimited DatastaleGeneMedicine Co., Ltd.Phase 2

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

Head and Neck Cancer; Malignant Melanoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#monoclonal-antibody#MalignantMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

GP2013 - A Proposed biosimilar rituximab (GP2013 - A Proposed biosimilar rituximab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleAbbViePhase 3

adalimumab biosimilar (GP2017, GP2017 (adalimumab biosimilar))

Ankylosing Spondylitis · Ankylosing Spondylitis

#AnkylosingSpondylitis#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active

10 / 20 pages

← PreviousNext →